EMFO LLC’s BioMarin Pharmaceuticals BMRN Stock Holding History

EMFO LLC’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-1,085	Closed	-$112K	–	311
2022 Q4	$112K	Hold	1,085	–	–	0.11%	114
2022 Q3	$92K	Hold	1,085	–	–	0.09%	139
2022 Q2	$90K	Hold	1,085	–	–	0.09%	142
2022 Q1	$84K	Hold	1,085	–	–	0.08%	162
2021 Q4	$96K	Sell	1,085 -52	-5%	-$4.29K	0.08%	147
2021 Q3	$88K	Hold	1,137	–	–	0.08%	158
2021 Q2	$95K	Buy	+1,137	New	+$90.1K	0.08%	153

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EMFO LLC's BMRN Position: Q1 2023 in Review

EMFO LLC sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2023, closing a stake of 1,085 shares — an estimated $112K sold.

EMFO LLC first reported a position in BMRN in Q2 2021 and held it in 7 quarters. The position peaked at $112K in Q4 2022. 552 funds tracked by Wall St. Rank hold BMRN as of Q1 2023.

EMFO LLC reported no remaining BioMarin Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
EMFO LLC sold 1,085 BioMarin Pharmaceuticals shares in Q1 2023, an estimated $112K.
EMFO LLC first reported a position in BioMarin Pharmaceuticals in Q2 2021 and held it in 7 quarters.
EMFO LLC's BioMarin Pharmaceuticals position peaked at $112K in Q4 2022.
552 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2023.

Based on EMFO LLC's 13F filing for Q1 2023, filed 8 May 2023.